Portal de Periódicos da CAPES

Renal Nerve-Mediated Erythropoietin Release Confers Cardioprotection During Remote Ischemic Preconditioning

2015; Japanese Circulation Society; Volume: 79; Issue: 7 Linguagem: Inglês

10.1253/circj.cj-14-1171

1347-4820

Toyoharu Oba, Hideo Yasukawa, Takanobu Nagata, Sachiko Kyogoku, Tomoko Minami, Michihide Nishihara, Hideki Ohshima, Kazutoshi Mawatari, Shoichiro Nohara, J Takahashi, Yusuke Sugi, Sachiyo Igata, Yoshiko Iwamoto, Hisashi Kai, Hidehiro Matsuoka, Makoto Takano, Hiroki Aoki, Yoshihiro Fukumoto, Tsutomu Imaizumi,

Cardiac Arrest and Resuscitation

Remote ischemic preconditioning (RIPC) induced by transient limb ischemia is a powerful innate mechanism of cardioprotection against ischemia. Several described mechanisms explain how RIPC may act through neural pathways or humoral factors; however, the mechanistic pathway linking the remote organ to the heart has not yet been fully elucidated. This study aimed to investigate the mechanisms underlying the RIPC-induced production of Janus kinase (JAK)-signal transducer and activator of the transcription (STAT)-activating cytokines and cardioprotection by using mouse and human models of RIPC.Screened circulating cardioprotective JAK-STAT-activating cytokines in mice unexpectedly revealed increased serum erythropoietin (EPO) levels after RIP induced by transient ischemia. In mice, RIPC rapidly upregulated EPO mRNA and its main transcriptional factor, hypoxia-inducible factor-1α (HIF1α), in the kidney. Laser Doppler blood flowmetry revealed a prompt reduction of renal blood flow (RBF) after RIPC. RIPC activated cardioprotective signaling pathways and the anti-apoptotic Bcl-xL pathway in the heart, and reduced infarct size. In mice, these effects were abolished by administration of an EPO-neutralizing antibody. Renal nerve denervation also abolished RIPC-induced RBF reduction, EPO production, and cardioprotection. In humans, transient limb ischemia of the upper arm reduced RBF and increased serum EPO levels.Based on the present data, we propose a novel RIPC mechanism in which inhibition of infarct size by RIPC is produced through the renal nerve-mediated reduction of RBF associated with activation of the HIF1α-EPO pathway.